GLP-1 Education
Oral Wegovy vs. Injectable: How Oral GLP-1 Medications Work Differently
The FDA approved oral semaglutide (Wegovy 50mg tablet) for weight loss in December 2025 — the first oral GLP-1 approved for obesity. Same molecule, very different pharmacokinetics.
What is oral semaglutide?
Oral semaglutide uses a technology called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) — a carrier molecule that helps semaglutide survive stomach acid and absorb through the stomach lining. Without it, the protein-based drug would be digested before reaching the bloodstream.
The result is the same active molecule as Ozempic and Wegovy injections — just delivered by pill instead of pen. Bioavailability is about 1% (vs ~89% for SC injection), which is why oral doses are much higher: 50mg oral achieves comparable blood levels to 2.4mg injected.
Oral vs. Injectable — Side by Side
| Factor | Injectable Semaglutide | Oral Semaglutide |
|---|---|---|
| Administration | Weekly subcutaneous injection (pen device) | Once-daily tablet swallowed with water |
| Frequency | Once per week | Once per day |
| Time to peak (Tmax) | ~1–3 days after injection | ~1 hour after swallowing |
| Food restriction | None — inject any time of day | Must take on empty stomach, 30 min before first food or drink |
| Bioavailability | ~89% (high — directly into tissue) | ~1% (low — requires SNAC absorption enhancer at higher doses) |
| Half-life | ~7 days (same molecule) | ~7 days (same molecule) |
| Drug level pattern | Large weekly wave — peaks 1–3 days post-injection, drops by end of week | Near-flat steady-state — tiny daily fluctuations due to long half-life |
| Approved doses | Wegovy: 0.25mg → 2.4mg; Ozempic: 0.25mg → 2mg | Oral Wegovy: 25mg (weeks 1–4) → 50mg; Rybelsus: 3mg → 14mg (T2D only) |
Why the drug level pattern looks different
With injectable semaglutide, you get a clear weekly wave: the drug peaks 1–3 days after injection, then gradually falls over the rest of the week before your next dose. By day 6–7, many people notice appetite returning slightly — a sign levels are dropping.
With oral semaglutide, the pattern is nearly flat. The pill absorbs quickly (peak in ~1 hour), but the drug's 7-day half-life means it decays very slowly. At steady state — which takes a few weeks to establish — daily levels fluctuate by less than 10% between peak and trough. You don't get the weekly highs and lows.
This means oral GLP-1 users are less likely to feel that "pre-dose slump" at the end of the week, but they must be consistent about daily dosing and strict about the fasting window.
⚠ Food timing is critical for oral GLP-1
This is the most important difference in daily practice: oral semaglutide absorption is highly food-dependent.
- •Take with no more than 4 oz (120 mL) of plain water
- •Wait at least 30 minutes before eating, drinking anything else, or taking other medications
- •Taking with food can reduce absorption by up to 70%, meaning you may not be getting the intended dose
What do the clinical trials show?
The OASIS 1 trial (published 2023, Lancet) tested oral semaglutide 50mg vs placebo in adults with obesity without diabetes. At 68 weeks:
- • Average weight loss: ~15.1% body weight
- • Placebo group: ~2.4% body weight
- • Responders (≥5% loss): 84% on oral semaglutide vs 26% placebo
Compare: injectable Wegovy (STEP 1) showed ~17.4% at 68 weeks. Oral is slightly less effective, likely due to bioavailability variability.
Who might prefer oral vs. injectable?
Oral might work better for you if:
- • You have needle anxiety or phobia
- • You prefer a daily routine to a weekly event
- • You dislike the weekly appetite fluctuation pattern
- • Travel or storage of injectable pens is inconvenient
Injectable might work better if:
- • You can't consistently maintain the fasting window
- • You take other morning medications that can't be separated
- • You prefer a once-weekly, "set and forget" approach
- • Cost or insurance coverage favors injectable
Track your oral GLP-1 drug levels
The Dose & Thrive calculator now supports oral semaglutide (Rybelsus and Oral Wegovy). See your estimated concentration and daily steady-state curve.
Open the Drug Level Calculator →Information based on published prescribing information and the OASIS 1 clinical trial (Knop et al. 2023, Lancet). Oral Wegovy (semaglutide 50mg) received FDA approval for chronic weight management in December 2025. Not medical advice — always consult your healthcare provider.